Adjuvant Therapy in High-Risk Cutaneous Squamous Cell Carcinoma: New Challenges

GV Schiappacasse¹²³*

Received: August 20, 2020;   Published: September 11, 2020

DOI: 10.32474/OAJOM.2020.04.000179

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Non-melanoma skin cancer is the most common tumor in the world; and cutaneous squamous cell carcinoma (cSCC) accounts for 20% of cases. It has a very good prognosis, except for the high-risk group. Studies of this group, despite its low frequency (5%), are extremely important because the cancer has a high risk of relapse and development of locoregional and distant metastasis. And this is directly correlated with higher and significant mortality. Therefore, since there is limited data on current adjuvant therapies after surgery, or the therapies are not beneficial, we propose to investigate the benefit of anti-PD-1 and epidermal growth factor receptor (EGFR) inhibitors as adjuvant therapies in high-risk cSCC as supported by translational research and based on the available evidence.

Keywords: Cutaneous Squamous Cell Carcinoma; High-Risk; Adjuvant; Immunotherapy; EGFR Inhibitors

Abstract| Introduction| Risk Factors| Histological characteristics| State of the Art in High-Risk cSCC| Adjuvant Therapies| New Perspectives for Adjuvant Therapies in High- Risk cSCC| What is the Optimal Duration of Adjuvant Therapy?| Conclusion| References|